FY2024 Earnings Estimate for Invivyd Issued By HC Wainwright

Invivyd, Inc. (NASDAQ:IVVD - Free Report) - Equities research analysts at HC Wainwright cut their FY2024 earnings estimates for shares of Invivyd in a note issued to investors on Tuesday, February 4th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings of ($1.64) per share for the year, down from their previous forecast of ($1.63). HC Wainwright currently has a "Buy" rating and a $10.00 target price on the stock. The consensus estimate for Invivyd's current full-year earnings is ($1.64) per share. HC Wainwright also issued estimates for Invivyd's Q4 2024 earnings at ($0.36) EPS.

Several other brokerages have also issued reports on IVVD. D. Boral Capital reiterated a "buy" rating and issued a $9.00 price objective on shares of Invivyd in a research report on Monday, February 3rd. EF Hutton Acquisition Co. I upgraded shares of Invivyd to a "strong-buy" rating in a report on Wednesday, October 30th. Finally, Morgan Stanley dropped their price objective on shares of Invivyd from $9.50 to $3.55 and set an "overweight" rating on the stock in a report on Wednesday, November 20th. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $7.89.

Invivyd Stock Up 3.0 %

NASDAQ IVVD traded up $0.06 during trading on Thursday, reaching $2.04. 27,285,427 shares of the stock traded hands, compared to its average volume of 36,383,976. Invivyd has a fifty-two week low of $0.35 and a fifty-two week high of $5.10. The firm has a market cap of $244.02 million, a price-to-earnings ratio of -1.04 and a beta of 0.61. The stock's 50-day moving average price is $0.60 and its 200 day moving average price is $0.84.

Hedge Funds Weigh In On Invivyd

A number of hedge funds have recently added to or reduced their stakes in the stock. State Street Corp lifted its holdings in shares of Invivyd by 3.7% during the 3rd quarter. State Street Corp now owns 1,018,640 shares of the company's stock worth $1,039,000 after acquiring an additional 35,904 shares during the period. Barclays PLC raised its position in Invivyd by 179.6% during the third quarter. Barclays PLC now owns 117,973 shares of the company's stock valued at $120,000 after purchasing an additional 75,780 shares in the last quarter. Cubist Systematic Strategies LLC lifted its stake in Invivyd by 66.1% during the second quarter. Cubist Systematic Strategies LLC now owns 134,452 shares of the company's stock worth $148,000 after purchasing an additional 53,499 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in shares of Invivyd in the 2nd quarter valued at $421,000. Finally, Proficio Capital Partners LLC bought a new position in shares of Invivyd in the 3rd quarter valued at $27,000. Institutional investors own 70.36% of the company's stock.

Insider Buying and Selling

In other news, Director Terrance Mcguire sold 150,000 shares of Invivyd stock in a transaction on Monday, December 9th. The stock was sold at an average price of $0.61, for a total transaction of $91,500.00. Following the completion of the sale, the director now owns 4,538,079 shares of the company's stock, valued at approximately $2,768,228.19. This trade represents a 3.20 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last 90 days, insiders sold 816,466 shares of company stock valued at $423,214. Company insiders own 17.90% of the company's stock.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.